koko体育app

欢迎来到《koko体育app 学报(医学版)》
前庭神经系统鞘瘤的药物剂量诊治发展方向

koko体育app: 钟平

钟平. 前庭神经鞘瘤的药物治疗前景[J]. koko体育app 学报(医学版), 2022, 53(4): 549-553. doi: 10.12182/20220760202
引用本文: 钟平. 前庭神经鞘瘤的药物治疗前景[J]. koko体育app 学报(医学版), 2022, 53(4): 549-553. doi:
ZHONG Ping. Prospects of Drug Therapy of Vestibular Schwannoma[J]. JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCE EDITION), 2022, 53(4): 549-553. doi: 10.12182/20220760202
Citation: ZHONG Ping. Prospects of Drug Therapy of Vestibular Schwannoma[J]. JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCE EDITION), 2022, 53(4): 549-553. doi:

栏目: 专家笔谈

前庭神经鞘瘤的药物治疗前景

doi: 
基金项目: 中国医学科学院医学与健康科技创新工程(No. 2019-I2M-5-008)和上海申康医院发展中心临床三年行动计划(No. SHDC2020CR1049B)资助

Prospects of Drug Therapy of Vestibular Schwannoma

  • 摘要: 前庭神经鞘瘤(vestibular schwannoma, VS)是中枢神经系统最常见的良性肿瘤之一。目前主要采用手术治疗、立体定向放射治疗及随访观察等,缺少可用于VS的药物治疗。虽然手术技术相对成熟,但并发症无法完全避免;且不同病例生长速度迥异,对放射治疗的敏感性也存在较大差异。随着分子生物学研究的不断深入,VS的生长机制研究大多聚焦于神经纤维蛋白2基因(neurofibromin 2, NF2)和merlin蛋白的相关上下游和受体蛋白酪氨酸激酶(receptor protein tyrosine kinase, RTK)、血管内皮生长因子受体(vascular endothelial growth factor receptor, VEGFR)、雷帕霉素靶蛋白复合物1(mammalian target of rapamycin complex 1, mTORC1)、血小板衍生生长因子受体(platelet derived growth factor receptor, PDGFR)等相应靶点。已报道的研究提示有相当多的药物对VS细胞的增殖都有抑制作用。虽然大部分研究都还在体外细胞实验和/或动物实验阶段,少部分进入临床Ⅰ~Ⅱ期研究,尚不能导向临床治疗;但据此可以全面了解VS药物治疗的现状和前景,有助于后续研究的开展。
  • [1] HUANG X, XU J, ZHONG P. The clinical feature of intracranial vestibular Schwannomas--A retrospective review of 1009 vestibular schwannomas in single hospital. Acta Neurochirurgical,2011,Suppl 53: 1833–1905.
    [2] ASTHAGIRI A R, PARRY D M, BUTMAN J A, et al. Neurofibromatosis type 2. Lancet,2009,373(9679): 1974–1986. doi:
    [3] HUANG X, XU J, XU M, et al. Functional outcome and complications after the microsurgical removal of giant vestibular schwannomas via the retrosigmoid approach: A retrospective review of 16-year experience in a single hospital. BMC Neurol, 2017, 17: 18[2023-04-17]. .
    [4] HUANG X, XU M, XU J, et al. Complications and management of large intracranial vestibular Schwannomas via the retrosigmoid approach. World Neurosurg,2017,99: 326–335. doi:
    [5] LONG J F, ZHANG Y, HUANG X, et al. A review of drug therapy in vestibular Schwannoma. Drug Des Devel Ther,2021,15: 75–85. doi:
    [6] ZHANG Y, LONG J F, REN J W, et al. Potential molecular biomarkers of vestibular Schwannoma growth: Progress and prospects. Front Oncol, 2021, 11: 731441[2023-04-17]. .
    [7] ROBINSON D R, WU Y M, LIN S F. The protein tyrosine kinase family of the human genome. Oncogene,2000,19(49): 5548–5557. doi:
    [8] CIARK J J, PROVENZANO M, DIGGELMANN H R, et al. The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular Schwannoma xenografts in nude mice: A preliminary study. Otol Neurotol,2008,29(6): 846–853. doi:
    [9] KARAJANNIS M A, LEGAULT G, HAGIWARA M, et al. Phase Ⅱ trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular Schwannomas. Neuro Oncol,2012,14(9): 1163–1170. doi:
    [10] ALTUNA X, LOPEZ J P, YU M, et al. Potential role of imatinib mesylate (gleevec, STI-571) in the treatment of vestibular Schwannoma. Otol Neurotol,2011,32(1): 163–170. doi:
    [11] MUKHERJEE J, KAMNASARAN D, BALASUBRAMANIAM A, et al. Human Schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by gleevec (imatinib mesylate). Cancer Res,2009,69(12): 5099–5107. doi:
    [12] AMMOUN S, SCHMID M C, TRINER J, et al. Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2. Neuro Oncol,2011,13(7): 759–766. doi:
    [13] SABHA N, AU K, AGNIHOTRI S, et al. Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells. PLoS One, 2012, 7(6): 10[2023-04-17]. .
    [14] PETRILLI A M, GARCIA J, BOTT M, et al. Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human Schwann cells. Oncotarget,2017,8(19): 31666–31681. doi:
    [15] ACEVEDO L M, BARILLAS S, WEIS S M, et al. Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood,2008,111(5): 2674–2680. doi:
    [16] PLOTKIN S R, STEMMER-RACHAMIMOV A O, BARKER F G, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. New Engl J Med,2009,361(4): 358–367. doi:
    [17] PLOTKIN S R, DUDA D G, MUZIKANSKY A, et al. Multicenter, prospective, phase Ⅱ and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular Schwannoma. J Clin Oncol,2019,37(35): 3446–3454. doi:
    [18] GUGEL I, KLUWE L, ZIPFEL J, et al. Minimal effect of bevacizumab treatment on residual vestibular schwannomas after partial resection in young neurofibromatosis type 2 patients. Cancers, 2019, 11 (12): 1862[2023-04-17]. .
    [19] SLUSARZ K M, MERKER V L, MUZIKANSKY A, et al. Long-term toxicity of bevacizumab therapy in neurofibromatosis2 patients. Cancer Chemother Pharmacol,2014,73(6): 1197–1204. doi:
    [20] RIINA H A, BURKHARDT J K, SANTILLAN A, et al. Short-term clinico-radiographic response to super-selective intra-arterial cerebral infusion of bevacizumab for the treatment of vestibular Schwannomas in neurofibromatosis type 2. Interv Neuroradiol,2012,18(2): 127–132. doi:
    [21] KARAJANNIS M A, HAGIWARA M, SCHREYER M, et al. Sustained imaging response and hearing preservation with low-dose beva-cizumab in sporadic vestibular Schwannoma. Neuro Oncol,2019,21(6): 822–824. doi:
    [22] TROUTMAN S, MOLEIRINHO S, KOTA S, et al. Crizotinib inhibits NF2-associated Schwannoma through inhibition of focal adhesion kinase 1. Oncotarget,2016,7(34): 54515–54525. doi:
    [23] WELLING D B, LASAK J M, AKHMAMETYEVA E, et al. cDNA microarray analysis of vestibular Schwannomas. Otol Neurotol,2002,23(5): 736–748. doi:
    [24] LEE T X, PACKER M D, HUANG J, et al. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant Schwannoma cells. Eur J Cancer,2009,45(9): 1709–1720. doi:
    [25] BUSH M L, OBLINGER J, BRENDEL V, et al. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular Schwannomas and meningiomas. Neuro Oncol,2011,13(9): 983–999. doi:
    [26] JACOB A, OBLINGER J, BUSH M L, et al. Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular Schwannomas. Laryngoscope,2012,122(1): 174–189. doi:
    [27] JAMES M F, STIVISON E, BEAUCHAMP R, et al. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types. Mol Cancer Res,2012,10(5): 649–659. doi:
    [28] GIOVANNINI M, BONNE N X, VITTE J, et al. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma. Neuro Oncol,2014,16(4): 493–504. doi:
    [29] KARAJANNIS M A, LEGAULT G, HAGIWARA M, et al. Phase Ⅱ study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular Schwannomas. Neuro Oncol,2014,16(2): 292–297. doi:
    [30] SONAM D, DANIEL R, STANKOVIC K M. Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and Schwann cells. Cancer Biol Ther,2015,16(1): 170–175. doi:
    [31] KANDATHIL C K, DILWALI S, WU C, et al. Aspirin intake correlates with halted growth of sporadic vestibular Schwannomain vivo. Otol Neurotol,2014,35(2): 353–357. doi:
    [32] SAGERS J E, BROWN A S, VASILIJIC S, et al. Publisher correction: Computational repositioning and preclinical validation of mifepristone for human vestibular Schwannoma. Sci Rep, 2018, 8 (1): 17449[2023-04-17]. .
    [33] OUERDANI A, GOUTAGNY S, KALAMARIDES M, et al. Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular Schwannomas of patients with neurofibromatosis type 2. Cancer Chemother Pharmacol,2016,77(6): 1263–1273. doi:
  • 加载中
计量
  • 文章访问数:  1
  • HTML全文浏览量:  0
  • PDF下载量:  0
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-05-09
  • 修回日期:  2023-07-09
  • 刊出日期:  2023-07-22

目录

    /

    返回文章
    返回
    var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?646a7d1033ff411d5d7be270f3397897"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })(); koko体育-koko体育app koko体育-koko体育网页版koko体育app koko体育-全站app下载(官网) m6米乐app|下载 m6米乐app|主頁欢迎您!!